Literature DB >> 15166530

The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution.

Olivier Lambotte1, Marie-Laure Chaix, Brigitte Gubler, Nadine Nasreddine, Christine Wallon, Cécile Goujard, Christine Rouzioux, Yassine Taoufik, Jean-François Delfraissy.   

Abstract

OBJECTIVE: To investigate the dynamics of the lymphocyte HIV reservoir in patients on prolonged and effective highly active antiretroviral therapy (HAART).
DESIGN: Nine HAART-treated patients were selected on the basis of long-term infection and long-term undetectable plasma viral RNA. Five patients had received antiretroviral therapy before HAART. We compared a polymorphic region of the env gene (C2V4), and the part of the pol gene encoding the reverse transcriptase in pre-HAART plasma and in the reservoir lymphocytes during HAART; the first plasma sample taken after structured treatment interruption was also studied in three patients.
METHODS: Both regions of interest were amplified from plasma HIV RNA and cellular proviral DNA, then cloned, sequenced and subjected to phylogenetic analysis.
RESULTS: Diversity of the lymphocyte reservoir was found in six of nine patients. Archiving of pre-HAART plasma clones was observed in six of nine patients. 'Wild-type' and zidovudine-resistant strains co-existed in reservoir T cells of two pre-HAART treated patients. In three patients, no resistant virus was found in the T-cell reservoir despite the detection of resistant virus in pre-HAART plasmas. However, virus archiving was documented in two of these three patients on the basis of C2V4 analysis. Latently infected T cells only partly accounted for the plasma viral load rebound after structured treatment interruption.
CONCLUSIONS: The HIV lymphocyte reservoir is dynamic. Its diversity results mainly from successive archiving of circulating plasma viruses during the course of HIV infection. Archiving of resistant virus must be taken into account in therapeutic decisions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15166530     DOI: 10.1097/00002030-200405210-00008

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  26 in total

Review 1.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

2.  Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Authors:  Daniel A Donahue; Sophie M Bastarache; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

3.  Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults.

Authors:  Emily C Liang; Lindsay Sceats; Nicholas L Bayless; Dara M Strauss-Albee; Jessica Kubo; Philip M Grant; David Furman; Manisha Desai; David A Katzenstein; Mark M Davis; Andrew R Zolopa; Catherine A Blish
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

4.  HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay.

Authors:  Sara Sunshine; Rory Kirchner; Sami S Amr; Leandra Mansur; Rimma Shakhbatyan; Michelle Kim; Alberto Bosque; Robert F Siliciano; Vicente Planelles; Oliver Hofmann; Shannan Ho Sui; Jonathan Z Li
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

Review 5.  Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs.

Authors:  Mayte Coiras; María Rosa López-Huertas; Mayte Pérez-Olmeda; José Alcamí
Journal:  Nat Rev Microbiol       Date:  2009-11       Impact factor: 60.633

6.  High discordance in blood and genital tract HIV-1 drug resistance in Indian women failing first-line therapy.

Authors:  Shanmugam Saravanan; Selvamurthi Gomathi; Allison Delong; Bagavathi Kausalya; Sathasivam Sivamalar; Selvamuthu Poongulali; Katherine Brooks; Nagalingeswaran Kumarasamy; Pachamuthu Balakrishnan; Sunil S Solomon; Susan Cu-Uvin; Rami Kantor
Journal:  J Antimicrob Chemother       Date:  2018-08-01       Impact factor: 5.790

7.  Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth.

Authors:  Zabrina L Brumme; Hanwei Sudderuddin; Carrie Ziemniak; Katherine Luzuriaga; Bradley R Jones; Jeffrey B Joy; Coleen K Cunningham; Thomas Greenough; Deborah Persaud
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

8.  A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.

Authors:  Daphne Monie; Rachel P Simmons; Richard E Nettles; Tara L Kieffer; Yan Zhou; Haili Zhang; Sharon Karmon; Roxann Ingersoll; Karen Chadwick; Hao Zhang; Joseph B Margolick; Thomas C Quinn; Stuart C Ray; Megan Wind-Rotolo; Michael Miller; Deborah Persaud; Robert F Siliciano
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

9.  Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.

Authors:  Sophie Reuse; Miriam Calao; Kabamba Kabeya; Allan Guiguen; Jean-Stéphane Gatot; Vincent Quivy; Caroline Vanhulle; Aurélia Lamine; Dolores Vaira; Dominique Demonte; Valérie Martinelli; Emmanuelle Veithen; Thomas Cherrier; Véronique Avettand; Solène Poutrel; Jacques Piette; Yvan de Launoit; Michel Moutschen; Arsène Burny; Christine Rouzioux; Stéphane De Wit; Georges Herbein; Olivier Rohr; Yves Collette; Olivier Lambotte; Nathan Clumeck; Carine Van Lint
Journal:  PLoS One       Date:  2009-06-30       Impact factor: 3.240

10.  Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.

Authors:  A Gonzalez-Serna; J E Min; C Woods; D Chan; V D Lima; J S G Montaner; P R Harrigan; L C Swenson
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.